Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00789373 |
This study will compare progression-free survival in patients with advanced non-squamous Non-Small Cell Lung Cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance pemetrexed or placebo.
Condition | Intervention | Phase |
---|---|---|
Non-Small Cell Lung Cancer |
Drug: Pemetrexed Drug: Cisplatin Drug: Placebo Other: Best Supportive Care |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer. |
Estimated Enrollment: | 600 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | May 2012 |
Estimated Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
pemetrexed and cisplatin followed by pemetrexed plus best supportive care
|
Drug: Pemetrexed
Induction therapy: 500 mg/m2, IV, on Day 1 of each 21-day cycle x 4 cycles
Drug: Cisplatin
Induction therapy: Cisplatin: 75 mg/m2, IV, on Day 1 of each 21-day cycle x 4 cycles
Drug: Pemetrexed
Maintenance therapy: 500 mg/m2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
Other: Best Supportive Care
Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
|
B: Placebo Comparator
pemetrexed and cisplatin followed by placebo plus best supportive care
|
Drug: Pemetrexed
Induction therapy: 500 mg/m2, IV, on Day 1 of each 21-day cycle x 4 cycles
Drug: Cisplatin
Induction therapy: Cisplatin: 75 mg/m2, IV, on Day 1 of each 21-day cycle x 4 cycles
Drug: Placebo
Maintenance therapy: Normal saline (0.9% sodium chloride) administered intravenously on Day 1 every 21-day cycle until progressive disease or treatment discontinuation.
Other: Best Supportive Care
Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for the Induction Phase:
Exclusion Criteria for the Induction Phase:
Inclusion criteria at Randomization for the Maintenance Phase:
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) | 1-317-615-4559 |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Responsible Party: | Eli Lilly and Company ( Chief Medical Officer ) |
Study ID Numbers: | 12560, H3E-EW-S124 |
Study First Received: | November 10, 2008 |
Last Updated: | December 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00789373 |
Health Authority: | United States: Food and Drug Administration |
Folic Acid Pemetrexed Thoracic Neoplasms Non-small cell lung cancer Cisplatin Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Antimetabolites Respiratory Tract Neoplasms Neoplasms by Histologic Type Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs |
Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses |